Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Names OGT First High-Throughput Microarray Certified Service Provider

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Gene Technology and Agilent Technologies announced today that OGT has secured a new Agilent certification level and will be the company's first High-Throughput Microarray Certified Service Provider.

The designation is intended to validate OGT's use of Agilent microarrays for high-throughput and large-scale microarray studies, such as those provided through OGT's genomic services.

The certification follows an assessment of OGT's Genefficiency, a high-throughput genomics service that relies on high density, high sensitivity microarrays, including Agilent microarrays and customized arrays.

Oxford, UK-based OGT has been an Agilent microarray Certified Service Provider for nearly two years.

"OGT has been very successful integrating Agilent Automation Solution instrumentation and Agilent microarrays for an efficient laboratory workflow," Chris Grimley, senior marketing director for Agilent Technologies' genomics business, said in a statement. "We are confident that customers will benefit form the combination of Agilent products and OGT high-throughput service."

OGT recently generated array comparative genomic hybridization copy number data on some 22,000 samples for the Wellcome Trust Case Control Consortium over the course of 20 weeks, the firms noted.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.